Weight matters: new study tracks drug levels in breast cancer patients

NCT ID NCT07195344

Recruiting now Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is investigating whether a patient's body weight changes how the drug Trastuzumab-Deruxtecan (T-DXd) behaves in the body. Researchers will compare drug levels and side effects between normal-weight and overweight or obese patients with advanced breast cancer. The goal is to see if weight-based dosing adjustments could improve treatment safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trastuzumab-Deruxtecan (T-DXd)
What this could lead to: If successful, this could help doctors personalize dosing of T-DXd based on a patient's weight, potentially improving effectiveness and reducing toxicity.
What could go wrong: This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and results might not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC BREAST CANCERS

Contacts and locations

Locations

CHU de Nîmes
RECRUITING

Nîmes, France
Centre Eugène Marquis
RECRUITING

Rennes, France
Centre Georges François Leclerc
NOT_YET_RECRUITING

Dijon, France
Centre Oscar Lambret
RECRUITING

Lille, France
Centre Paul Strauss
RECRUITING

Strasbourg, France
IUCT-O
RECRUITING

Toulouse, France
Institut Curie - Site Paris
NOT_YET_RECRUITING

Paris, France
Institut Paoli Calmettes
NOT_YET_RECRUITING

Marseille, France
Institut de Cancérologie de Lorraine
NOT_YET_RECRUITING

Vandœuvre-lès-Nancy, France
Institut de Cancérologie de l'Ouest - Site Angers
NOT_YET_RECRUITING

Angers, France
Institut de Cancérologie de l'Ouest - Site Saint Herblain
NOT_YET_RECRUITING

Saint-Herblain, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.